Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

The patent cliff: rise of the generics

Twenty blockbuster drugs are set to go off patent within the next few years, leading big pharma into a new era of R&D. Elisabeth Fischer finds out how major pharmaceutical firms are planning to handle the long-dreaded patent cliff, embracing new business strategies to stay ahead of competitors from the generics market.

Go Top